Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FGFR1 |
Variant | E138* |
Impact List | nonsense |
Protein Effect | unknown |
Gene Variant Descriptions | FGFR1 E138* results in a premature truncation of the Fgfr1 protein at amino acid 138 of 822 (UniProt.org). E138* results in a loss of multiple functional domains (UniProt.org), but also results in similar cell proliferation and viability compared to wild-type Fgfr1 in culture (PMID: 29533785), and therefore, its effect on Fgfr1 protein function is unknown. |
Associated Drug Resistance | |
Category Variants Paths |
FGFR1 mutant FGFR1 E138* |
Transcript | NM_023110.3 |
gDNA | chr8:g.38428382C>A |
cDNA | c.412G>T |
Protein | p.E138* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001174063 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001174063.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001174063.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001174065 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001174065.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001174065.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001354367.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001354367.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001354369.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001354369.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_001410922.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_015850 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_015850.3 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_015850.4 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_023110 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_023110.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
NM_023110.3 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716303 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716303.3 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716303.4 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716304 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716304.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716304.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716306 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716307 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716307.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_006716307.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544449 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544449.1 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544449.2 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544450 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544450.2 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544450.3 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544451 | chr8:g.38426164C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544451.1 | chr8:g.38426164C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_011544451.1 | chr8:g.38426164C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013221 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013221.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013221.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013222 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013222.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013223 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013224 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013224.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013225 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013225.2 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013225.3 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013227 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013227.1 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013227.2 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013229 | chr8:g.38418274C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013229.2 | chr8:g.38418274C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013230 | chr8:g.38418274C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_017013230.1 | chr8:g.38418274C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_047421569.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_047421570.1 | chr8:g.38428382C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
XM_047421572.1 | chr8:g.38427956C>A | c.412G>T | p.E138* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FGFR1 mutant | transitional cell carcinoma | predicted - sensitive | Erdafitinib | Phase II | Actionable | In a Phase II trial, Balversa (erdafitinib) treatment resulted in an objective response rate of 42% (40/96, 3 complete response, 37 partial response) and a disease control rate of 80% in patients with metastatic or unresectable urothelial carcinoma harboring FGFR alterations (J Clin Oncol 36, 2018 (suppl; abstr 4503); NCT02365597). | detail... |
FGFR1 mutant | Advanced Solid Tumor | predicted - sensitive | ICP-192 | Phase I | Actionable | In a Phase I trial, ICP-192 (gunagratinib) was well-tolerated, and resulted in an overall response rate or 33.3% (4/12, 1 complete response, 3 partial response) and a disease control rate of 91.7% (11/12) in patients with advanced solid tumors harboring FGF/FGFR gene aberrations (J Clin Oncol 39, 2021 (suppl 15; abstr 4092); NCT03758664). | detail... |
FGFR1 mutant | Advanced Solid Tumor | predicted - sensitive | Zoligratinib | Phase I | Actionable | In a Phase I trial, Debio 1347 treatment resulted in partial response in 10.5% (6/57) and stable disease in 28.1% (16/57) of patients with advanced solid tumors harboring genomic alterations of FGFR1/2/3, including amplifications, fusions, and mutations (PMID: 30745300; NCT01948297). | 30745300 |
FGFR1 mutant | Advanced Solid Tumor | predicted - sensitive | Erdafitinib | Case Reports/Case Series | Actionable | In a Phase II trial (MATCH), Balversa (erdafitinib) treatment resulted in an objective response rate of 16% (4/25), median progression-free survival of 3.6 months, and median overall survival of 11.0 months in patients with advanced solid tumors harboring FGFR1, FGFR2, or FGFR3 mutations or fusions (PMID: 38603650; NCT02465060). | 38603650 |
FGFR1 mutant | Advanced Solid Tumor | sensitive | Pemigatinib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a variety of cancer cell lines harboring mutations in FGFR1, FGFR2, and/or FGFR3 demonstrated sensitivity to Pemazyre (pemigatinib) in culture and in cell line xenograft models, resulting in inhibition of tumor growth (Cancer Res 2015;75(15 Suppl):Abstract nr 771). | detail... |
CKB CORE allows for only a limited number of monthly page views for un-registered users. However, registration is free and allows for unlimited browsing of the CKB CORE content.
You have reached the monthly page view limit. For continued free access to CKB CORE, please register below: